Does Dr. ABDUL ABDELLATIF have financial conflicts of interest?

Dr. ABDUL ABDELLATIF (M.D.) has received a total of $1,605,528 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,478,405 in personal promotional payouts (consulting, meals, travel) and $127,123 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ABDUL ABDELLATIF?

According to CMS Open Payments data, Dr. ABDUL ABDELLATIF received funding from MALLINCKRODT HOSPITAL PRODUCTS ($426,235), HORIZON THERAPEUTICS PLC ($334,229), and AURINIA PHARMA U.S ($165,831).

Does Dr. ABDUL ABDELLATIF receive research grants or speaking fees?

Dr. ABDUL ABDELLATIF has received $1,478,405 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $127,123 in clinical research grants.

DR. ABDUL ABDELLATIF

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: WEBSTER, TX 77598

NPI Number: 1164560595

LIFETIME INDUSTRY VALUE

$1,605,528

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABDELLATIF is a verified Internal Medicine, Nephrology practitioner based in WEBSTER, TX.

Between 2021 and 2025, Dr. ABDELLATIF had an overall industry promotional and research financial footprint of $1,605,528 as recorded in the federal CMS Open Payments database.

$1,478,405 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$127,123 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDELLATIF's primary funding source is MALLINCKRODT HOSPITAL PRODUCTS, which accounts for $426,235 (representing 26.5% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MALLINCKRODT HOSPITAL PRODUCTS

Rank 1

$426,235

26.5%

HORIZON THERAPEUTICS PLC

Rank 2

$334,229

20.8%

AURINIA PHARMA U.S

Rank 3

$165,831

10.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.